Tesi 1989.

Methods	Double‐blind, placebo‐controlled randomised trial, allocation concealment unclear, method of random sequence generation not stated. Run‐in period: none. Drop‐outs and study withdrawals: no. Intention‐to‐treat: yes. Baseline characteristics comparable between two groups.
Participants	Country: Italy, 20 participants: Age: range 44 to 70 years; males: 11; females: 9; co‐morbidity not stated. Inclusion criteria: PAOD and IC diagnosed by clinical examination and ABI. Exclusion criteria: obesity, smoking, previous arterial surgery, AMI, angina pectoris.
Interventions	Treatment group: 10 participants: LMWH 8,000 U s.c. o.d. Control group: 10 participants: placebo sc od (indistinguishable from treatment). Duration: six months. Compliance: evaluated.
Outcomes	MWD, ABI, thrombotic complications, major and minor bleeding events.
Notes	Bar graphs only provided for MWD. No data provided by primary author. Intensity of walking test not stated.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear

Abbreviations:
 ABI: ankle/brachial index
 AMI: acute myocardial infarction
 ASA: acetylsalicylic acid
 IC: intermittent claudication
 INR: international normalised ratio
 LMWH: low molecular weight heparin
 MWD: maximum walking distance
 o.d.: once daily
 PAOD: peripheral arterial obstructive disease
 PFWD: pain free walking distance
 s.c.: subcutaneously
 SD: standard deviation
 SEM: standard error of the mean
 TIA: transient ischaemic attack
 t.i.d.: tris in diem (three times daily)
 UA: unstable angina